Private Advisor Group LLC Reduces Stock Holdings in Novo Nordisk A/S $NVO

Private Advisor Group LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 20.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 70,000 shares of the company’s stock after selling 17,770 shares during the period. Private Advisor Group LLC’s holdings in Novo Nordisk A/S were worth $2,573,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Boston Partners acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $310,199,000. Price T Rowe Associates Inc. MD lifted its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares during the last quarter. Voloridge Investment Management LLC grew its position in Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after acquiring an additional 4,302,126 shares during the period. Bank of Montreal Can increased its stake in Novo Nordisk A/S by 138.9% during the fourth quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock worth $128,514,000 after acquiring an additional 1,468,409 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in Novo Nordisk A/S during the fourth quarter worth $59,882,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched Awiqli, the world’s first once-weekly basal insulin, in India, expanding its diabetes portfolio in one of the world’s largest and fastest-growing diabetes markets. The rollout could provide a new growth avenue and reinforces the company’s leadership in diabetes care. Article Title
• Positive Sentiment: Another report highlighted the India insulin launch as a meaningful innovation for diabetes treatment, which may improve investor sentiment around Novo Nordisk’s long-term pipeline and international expansion. Article Title
• Positive Sentiment: A separate piece said Novo Nordisk remains undervalued despite the Wegovy label update, suggesting the market may still be pricing in a cautious outlook even as the company preserves a strong long-term obesity-drug story. Article Title
• Neutral Sentiment: Novo Nordisk also expanded its collaboration with MAHE’s GBS in pharmacometrics, a strategic but likely modest near-term market-moving development. Article Title
• Neutral Sentiment: The company signed a pact with Vivani for a long-lasting semaglutide implant, which adds to its pipeline optionality but is still early-stage and not an immediate earnings driver. Article Title
• Negative Sentiment: Recent prescription-tracker data pointed to a slowdown in demand for the oral Wegovy pill in the U.S., raising concerns that growth in Novo Nordisk’s GLP-1 franchise may be cooling after a strong run. Article Title
• Negative Sentiment: The stock also came under pressure in recent trading after falling more than the broader market, reflecting investor caution around near-term GLP-1 growth trends and valuation. Article Title

Analyst Ratings Changes

NVO has been the topic of several recent analyst reports. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Finally, HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday. Five research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

NVO stock opened at $48.93 on Friday. The business’s fifty day moving average price is $45.39 and its 200 day moving average price is $45.85. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $218.48 billion, a PE ratio of 11.49, a P/E/G ratio of 4.46 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.